GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
WEB1 day ago · Oct 9 (Reuters) - GSK (GSK.L) has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued version of the heartburn drug Zantac caused cancer ...
Pharmaceuticals giant GSK to pay $2.2bn to settle Zantac lawsuits
WEBGSK has reached agreements with law firms representing around 80,000 claimants. UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts ...
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
WEB1 day ago · Oct. 9, 2024. The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who claim that they developed cancer after ...
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK announces independent Consumer Healthcare company is to …
WEBFeb 22, 2022 · GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon.
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
WEBLONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 · GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology.
GSK completes acquisition of TESARO, an oncology focused ...
WEBGlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of …
GSK delivers strong 2022 performance with full year sales of £29.3 ...
WEBFeb 1, 2023 · Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions.
- Some results have been removed